Teclistamab: all 47 studies that test it

Page 1 of 1. Open to participants first (31), then studies with results posted, then the rest; newest registration first within each.

• Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingNCT07887984Phase 2/3
• Teclistamab In Waldenstrom's MacroglobulinemiaNot yet recruitingNCT07791498Phase 2
• Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07757412Phase 2
• A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingNCT07740486Phase 3
• GMMG-HD11/DSMM XXI/64007957MMY3010Not yet recruitingNCT07671287Phase 3
• Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingNCT07657312Phase 2
• Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
• A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingNCT07638683Phase 2
• Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5Not yet recruitingNCT07631208Phase 2
• Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingNCT07605416Phase 2
• Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingNCT07463807Phase 1/2
• Testing the Effect of Teclistamab on Recurrent Plasmablastic LymphomaRecruitingNCT07332507Phase 1
• Teclistamab-Daratumumab in AL AmyloidosisRecruitingNCT07110844Phase 2
• Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.RecruitingNCT07107529Phase 2
• A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingNCT07105059Phase 1
• Teclistamab in Newly Diagnosed Mayo Stage IIIB AL AmyloidosisRecruitingNCT07079423Phase 2
• Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingNCT06993675Phase 2
• Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingNCT06948084Phase 2
• Teclistamab in Previously Treated AL AmyloidosisRecruitingNCT06935162Phase 2
• Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple MyelomaNot yet recruitingNCT06880601Phase 2
• Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT06758375Phase 2
• Prospective Study of Teclistamab in the Treatment of Systemic AL AmyloidosisRecruitingNCT06699394Not applicable
• Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsRecruitingNCT06505369Phase 2
• Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingNCT06465316Phase 1
• Plan Development for Giving Teclistamab in the Outpatient SettingRecruitingNCT06251076Phase 4
• Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)RecruitingNCT06100237Phase 2
• Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3
• Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingNCT05469893Phase 2
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Phase 3
• A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruitingNCT07030517Phase 4
• A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) AmyloidosisActive, not recruitingNCT06649695Phase 2
• ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple MyelomaTerminatedNCT06588660Phase 1
• A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06577025Phase 2
• A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06425991Phase 1
• Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnNCT06352866Phase 2
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
• MMRC Horizon One: RRMM (MMRC-099)Active, not recruitingNCT06171685Phase 2
• Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaActive, not recruitingNCT05849610Phase 2
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05338775Phase 1
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04696809Phase 1/2
• A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04586426Phase 1/2
• A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Phase 2
• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03145181Phase 1

← Teclistamab overview